Star Equity Holdings, Inc. Announces 2022 Third Quarter Financial Results
Reported a 55% increase in Q3 2022 consolidated gross profit versus Q3 2021
Construction division reported a significant gross margin improvement
Following the sale of a portion of our Healthcare business in early 2021, all financial results for the 2022 and 2021 reporting periods, unless stated otherwise, relate to continuing operations, which include the Healthcare, Construction, and Investments divisions.
Third Quarter 2022 Financial Highlights vs. Third Quarter 2021 (unaudited)
- Revenues decreased by 16.0% to
$24 .2 million from$28.9 million . - Gross profit increased by 54.8% to
$5.8 million from$3 .7 million. - Net loss from continuing operations was
$1 .9 million (or$0.12 per basic and diluted share) compared to a net loss from continuing operations of$2.1 million (or$0.42 per basic and diluted share). - Non-GAAP adjusted net income from continuing operations was
$0.8 million (or$0.05 per diluted share) compared to a loss of$1.5 million (or$0.28 per diluted share). - Non-GAAP adjusted EBITDA from continuing operations was
$1 .5 million versus a loss of$0.6 million .
Year to Date 2022 Financial Highlights vs. Year to Date 2021 (unaudited)
- Revenues increased by 3.9% to
$80.0 million from$77 .0 million. - Gross profit increased by 98.9% to
$16.6 million from$8 .3 million. - Net loss from continuing operations was
$7.2 million (or$0.49 per basic and diluted share) compared to a net loss from continuing operations of$4.5 million (or$0.90 per basic and diluted share). - Non-GAAP adjusted net income from continuing operations was
$0.5 million (or$0.04 per diluted share) compared to a loss of$6.9 million (or$1.36 per diluted share). - Non-GAAP adjusted EBITDA from continuing operations was
$2 .9 million versus a loss of$4 .5 million. - As of
September 30, 2022 , cash and cash equivalents increased to$8.5 million from$5 .6 million; net debt, defined as total debt less total cash and cash equivalents, decreased to$3 .3 million from$8.5 million .
Revenues
The Company’s third quarter 2022 revenues decreased 16.0% to
Revenues in $ thousands | Q3 2022 | Q3 2021 | % change | 9M 2022 | 9M 2021 | % change | ||||||||||||||||
Healthcare | $ | 13,137 | $ | 14,807 | (11.3 | )% | $ | 40,467 | $ | 42,984 | (5.9 | )% | ||||||||||
Construction | 11,107 | 14,052 | (21.0 | )% | 39,544 | 34,035 | 16.2 | % | ||||||||||||||
Investments | 159 | 475 | (66.5 | )% | 475 | 475 | — | % | ||||||||||||||
Intersegment elimination | (159 | ) | (475 | ) | (66.5 | )% | (475 | ) | (475 | ) | — | % | ||||||||||
Total Revenues | $ | 24,244 | $ | 28,859 | (16.0 | )% | $ | 80,011 | $ | 77,019 | 3.9 | % |
Our Healthcare third quarter 2022 and year to date 2022 revenue decreased 11.3% and 5.9%, respectively, versus the prior year periods, driven primarily by lower scanning revenue due to the continuing national shortage of Nuclear Medicine Technologists.
Our Construction third quarter 2022 revenue decreased 21.0% and year to date 2022 revenue increased 16.2% versus the prior year periods. The decrease in third quarter 2022 revenue was driven primarily by the timing of revenue recognition on certain projects. The year to date 2022 increase was due to large commercial projects at KBS. Construction division third quarter 2022 revenue accounted for 45.8% of Star Equity’s total revenue.
Gross Profit
Gross profit (loss) in $ thousands | Q3 2022 | Q3 2021 | % change | 9M 2022 | 9M 2021 | % change | ||||||||||||||||
Healthcare | $ | 2,725 | $ | 3,256 | (16.3 | )% | $ | 9,579 | $ | 9,263 | 3.4 | % | ||||||||||
Healthcare gross margin | 20.7 | % | 22.0 | % | (1.3 | )% | 23.7 | % | 21.5 | % | 2.2 | % | ||||||||||
Construction | 3,132 | 541 | 478.9 | % | 7,203 | (759 | ) | 1,049.0 | % | |||||||||||||
Construction gross margin | 28.2 | % | 3.8 | % | 24.4 | % | 18.2 | % | (2.2 | )% | 20.4 | % | ||||||||||
Investments | 100 | 425 | (76.5 | )% | 253 | 299 | (15.4 | )% | ||||||||||||||
Investments gross margin | — | — | — | % | — | — | — | % | ||||||||||||||
Intersegment elimination | (158 | ) | (475 | ) | (66.7 | )% | (474 | ) | (475 | ) | (0.2 | )% | ||||||||||
Total gross profit | $ | 5,799 | $ | 3,747 | 54.8 | % | $ | 16,561 | $ | 8,328 | 98.9 | % | ||||||||||
Total gross margin | 23.9 | % | 13.0 | % | 10.9 | % | 20.7 | % | 10.8 | % | 9.9 | % |
Healthcare third quarter 2022 gross profit decreased 16.3% and year to date 2022 gross profit increased 3.4% versus the prior year period, respectively. The third quarter 2022 gross profit decrease was driven by lower scanning revenue due to the continuing national shortage of Nuclear Medicine Technologists, while year to date 2022 was driven by an improved mix of product and service revenues.
Construction third quarter 2022 and year to date 2022 gross profit increased 478.9% and 1,049.0% from the prior year period, due to an increase in revenue during the period and significantly increased pricing levels.
Operating Expenses
On a consolidated basis, third quarter 2022 and year to date 2022 sales, general and administrative (“SG&A”) expenses increased by
Net Income
Third quarter 2022 net loss from continuing operations was
Year to date 2022 net loss from continuing operations was
Non-GAAP Adjusted EBITDA
Third quarter 2022 non-GAAP adjusted EBITDA from continuing operations was
Operating Cash Flow
Third quarter 2022 cash flow from operations was an outflow of
Preferred Stock Dividends
In each quarter of 2022, the Company’s board of directors declared cash dividends to holders of our Series A Preferred Stock of
Conference Call Information
A conference call is scheduled for today,
If you have any questions, either prior to or after our scheduled
Use of Non-GAAP Financial Measures by
This release presents the non-GAAP financial measures “adjusted net income (loss),” “adjusted net income (loss) per basic and diluted share,” and “adjusted EBITDA from continuing operations.” The most directly comparable measures for these non-GAAP financial measures are “net income (loss),” “net income (loss) per basic and diluted share,” and “cash flows from operating activities.” The Company has included below unaudited adjusted financial information, which presents the Company’s results of operations after excluding acquired intangible asset amortization, unrealized gain (loss) on equity securities and derivatives, litigation costs, non-recurring gain on disposals, one time severance costs, financing costs, COVID-19 protection equipment, gain or loss from loan forgiveness, and income tax adjustments. Further excluded in the measure of adjusted EBITDA are stock-based compensation, interest, taxes, depreciation, and amortization.
A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s report on Form 8-K filed with the
About
Healthcare
Our Healthcare division designs, manufactures, and distributes diagnostic medical imaging products and provides mobile imaging services. Our Healthcare division operates in two businesses: (i) diagnostic services and (ii) diagnostic imaging. The diagnostic services business offers imaging services to healthcare providers as an outsourced alternative to purchasing and operating their own equipment. The diagnostic imaging business develops, sells, and maintains solid-state gamma cameras.
Construction
Our Construction division manufactures modular housing units for commercial and residential real estate projects and operates in two businesses: (i) modular building manufacturing and (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations for professional builders.
Investments
Our Investments division manages and finances the Company’s real estate assets and investments.
Forward-Looking Statements
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release that are not statements of historical fact are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking Statements include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to acquisitions and related integration, development of commercially viable products, novel technologies, and modern applicable services, (ii) projections of income (including income/loss), EBITDA, earnings (including earnings/loss) per share, capital expenditures, cost reductions, capital structure or other financial items, (iii) the future financial performance of the Company or acquisition targets and (iv) the assumptions underlying or relating to any statement described above. Moreover, forward-looking statements necessarily involve assumptions on the Company’s part. These forward-looking statements generally are identified by the words “believe”, “expect”, “anticipate”, “estimate”, “project”, “intend”, “plan”, “should”, “may”, “will”, “would”, “will be”, “will continue” or similar expressions. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described above as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the substantial amount of debt of the Company and the Company’s ability to repay or refinance it or incur additional debt in the future; the Company’s need for a significant amount of cash to service and repay the debt and to pay dividends on the Company’s preferred stock; the restrictions contained in the debt agreements that limit the discretion of management in operating the business; legal, regulatory, political and economic risks in markets and public health crises that reduce economic activity and cause restrictions on operations (including the recent coronavirus COVID-19 outbreak); the length of time associated with servicing customers; losses of significant contracts or failure to get potential contracts being discussed; disruptions in the relationship with third party vendors; accounts receivable turnover; insufficient cash flows and resulting lack of liquidity; the Company's inability to expand the Company's business; unfavorable changes in the extensive governmental legislation and regulations governing healthcare providers and the provision of healthcare services and the competitive impact of such changes (including unfavorable changes to reimbursement policies); high costs of regulatory compliance; the liability and compliance costs regarding environmental regulations; the underlying condition of the technology support industry; the lack of product diversification; development and introduction of new technologies and intense competition in the healthcare industry; existing or increased competition; risks to the price and volatility of the Company’s common stock and preferred stock; stock volatility and in liquidity; risks to preferred stockholders of not receiving dividends and risks to the Company’s ability to pursue growth opportunities if the Company continues to pay dividends according to the terms of the Company’s preferred stock; the Company’s ability to execute on its business strategy (including any cost reduction plans); the Company’s failure to realize expected benefits of restructuring and cost-cutting actions; the Company’s ability to preserve and monetize its net operating losses; risks associated with the Company’s possible pursuit of acquisitions; the Company’s ability to consummate successful acquisitions and execute related integration, as well as factors related to the Company’s business including economic and financial market conditions generally and economic conditions in the Company’s markets; failure to keep pace with evolving technologies and difficulties integrating technologies; system failures; losses of key management personnel and the inability to attract and retain highly qualified management and personnel in the future; and the continued demand for and market acceptance of the Company’s services. For a detailed discussion of cautionary statements and risks that may affect the Company’s future results of operations and financial results, please refer to the Company’s filings with the
All forward-looking statements are necessarily only estimates of future results, and there can be no assurance that actual results will not differ materially from expectations, and, therefore, you are cautioned not to place undue reliance on such statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.
For more information contact: | ||
The Equity Group | ||
Chief Executive Officer | Senior Vice President | |
203-489-9508 | 212-836-9611 | |
rick.coleman@starequity.com | lcati@equityny.com |
(Financial tables follow)
Condensed Consolidated Statements of Operations
(Unaudited) (In thousands, except for per share amounts)
Three Months Ended |
Nine Months Ended |
|||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenues: | ||||||||||||||||
Healthcare | $ | 13,137 | $ | 14,807 | $ | 40,467 | $ | 42,984 | ||||||||
Construction | 11,107 | 14,052 | 39,544 | 34,035 | ||||||||||||
Investments | — | — | — | — | ||||||||||||
Total revenues | 24,244 | 28,859 | 80,011 | 77,019 | ||||||||||||
Cost of revenues: | ||||||||||||||||
Healthcare | 10,412 | 11,551 | 30,888 | 33,721 | ||||||||||||
Construction | 7,975 | 13,511 | 32,341 | 34,794 | ||||||||||||
Investments | 58 | 50 | 221 | 176 | ||||||||||||
Total cost of revenues | 18,445 | 25,112 | 63,450 | 68,691 | ||||||||||||
Gross profit | 5,799 | 3,747 | 16,561 | 8,328 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 6,860 | 5,201 | 20,515 | 15,839 | ||||||||||||
Amortization of intangible assets | 430 | 430 | 1,290 | 1,298 | ||||||||||||
Gain on sale of MD Office Solutions | — | — | — | (847 | ) | |||||||||||
Total operating expenses | 7,290 | 5,631 | 21,805 | 16,290 | ||||||||||||
Loss from operations | (1,491 | ) | (1,884 | ) | (5,244 | ) | (7,962 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Other income (expense), net | (575 | ) | 3 | (997 | ) | 4,208 | ||||||||||
Interest expense, net | (185 | ) | (260 | ) | (664 | ) | (732 | ) | ||||||||
Total other income (expense) | (760 | ) | (257 | ) | (1,661 | ) | 3,476 | |||||||||
Income (loss) from continuing operations before income taxes | (2,251 | ) | (2,141 | ) | (6,905 | ) | (4,486 | ) | ||||||||
Income tax benefit (provision) | 367 | — | (256 | ) | (34 | ) | ||||||||||
Income (loss) from continuing operations, net of tax | (1,884 | ) | (2,141 | ) | (7,161 | ) | (4,520 | ) | ||||||||
Income (loss) from discontinued operations, net of tax | — | — | — | 5,955 | ||||||||||||
Net income (loss) | (1,884 | ) | (2,141 | ) | (7,161 | ) | 1,435 | |||||||||
Deemed dividend on Series A perpetual preferred stock | (479 | ) | (479 | ) | (1,437 | ) | (1,437 | ) | ||||||||
Net income (loss) attributable to common shareholders | $ | (2,363 | ) | $ | (2,620 | ) | $ | (8,598 | ) | $ | (2 | ) | ||||
Net income (loss) per share—basic and diluted | ||||||||||||||||
Net income (loss) per share, continuing operations | $ | (0.12 | ) | $ | (0.42 | ) | $ | (0.49 | ) | $ | (0.90 | ) | ||||
Net income (loss) per share, discontinued operations | $ | — | $ | — | $ | — | $ | 1.19 | ||||||||
Net income (loss) per share—basic and diluted* | $ | (0.12 | ) | $ | (0.42 | ) | $ | (0.49 | ) | $ | 0.29 | |||||
Deemed dividend on Series A cumulative perpetual preferred stock per share | $ | (0.03 | ) | $ | (0.09 | ) | $ | (0.10 | ) | $ | (0.29 | ) | ||||
Net income (loss) per share, attributable to common shareholders—basic and diluted* | $ | (0.15 | ) | $ | (0.51 | ) | $ | (0.59 | ) | $ | — | |||||
Weighted-average shares outstanding—basic and diluted | 15,434 | 5,101 | 14,503 | 5,019 | ||||||||||||
Dividends declared per Series A perpetual preferred stock | $ | 0.25 | $ | 0.25 | $ | 0.75 | $ | 0.50 |
*Earnings per share may not add due to rounding
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
2021 |
|||||||
Assets: | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 8,503 | $ | 4,538 | |||
Restricted cash | 846 | 278 | |||||
Investments in equity securities | 3,180 | 47 | |||||
Lumber derivative contracts | — | 666 | |||||
Accounts receivable, net of allowances of |
13,754 | 15,811 | |||||
Inventories, net | 13,065 | 8,525 | |||||
Other current assets | 3,069 | 1,998 | |||||
Total current assets | 42,417 | 31,863 | |||||
Property and equipment, net | 8,499 | 8,918 | |||||
Operating lease right-of-use assets, net | 4,823 | 4,494 | |||||
Intangible assets, net | 13,782 | 15,072 | |||||
6,046 | 6,046 | ||||||
Other assets | 1,408 | 1,659 | |||||
Total assets | $ | 76,975 | $ | 68,052 | |||
Liabilities, Mezzanine Equity and Stockholders’ Equity: | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 6,094 | $ | 4,277 | |||
Accrued liabilities | 4,307 | 2,445 | |||||
Accrued compensation | 3,395 | 3,051 | |||||
Accrued warranty | 247 | 569 | |||||
Lumber derivative contracts | 635 | — | |||||
Billings in excess of costs and estimated profit | — | 312 | |||||
Deferred revenue | 3,801 | 2,457 | |||||
Short-term debt | 11,852 | 12,869 | |||||
Operating lease liabilities | 1,443 | 1,253 | |||||
Finance lease liabilities | 460 | 588 | |||||
Total current liabilities | 32,234 | 27,821 | |||||
Deferred tax liabilities | 298 | 72 | |||||
Operating lease liabilities, net of current portion | 3,463 | 3,299 | |||||
Finance lease liabilities, net of current portion | 459 | 706 | |||||
Other liabilities | 312 | 412 | |||||
Total liabilities | 36,766 | 32,310 | |||||
Preferred stock, |
— | 18,988 | |||||
Stockholders’ Equity: | |||||||
Preferred stock, |
18,988 | — | |||||
Preferred stock, |
— | — | |||||
Common stock, |
1 | — | |||||
(5,728 | ) | (5,728 | ) | ||||
Additional paid-in capital | 162,078 | 150,451 | |||||
Accumulated deficit | (135,130 | ) | (127,969 | ) | |||
Total stockholders’ equity | 40,209 | 16,754 | |||||
Total liabilities, mezzanine equity and stockholders’ equity | $ | 76,975 | $ | 68,052 |
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended |
Nine Months Ended |
|||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Net income (loss) from continuing operations | $ | (1,884 | ) | $ | (2,141 | ) | $ | (7,161 | ) | $ | (4,520 | ) | ||||
Acquired intangible amortization | 430 | 430 | 1,290 | 1,298 | ||||||||||||
Unrealized loss (gain) on equity securities (1) | 834 | (3 | ) | 834 | (17 | ) | ||||||||||
Unrealized loss (gain) on derivatives (2) | 153 | 95 | 1,298 | 398 | ||||||||||||
Litigation costs (3) | 1,187 | 88 | 2,955 | 213 | ||||||||||||
Gain on disposal of MD Office Solutions (4) | — | — | — | (847 | ) | |||||||||||
Tenant receivable (5) | — | — | — | 323 | ||||||||||||
Write off of software costs | — | — | — | 70 | ||||||||||||
Severance and retention costs (9) | 275 | — | 706 | — | ||||||||||||
Financing costs (6) | 132 | 52 | 369 | 231 | ||||||||||||
COVID-19 Protection Equipment (7) | — | 23 | — | 82 | ||||||||||||
SBA PPP Loan forgiveness (8) | — | — | — | (4,179 | ) | |||||||||||
Income tax (benefit) provision | (367 | ) | — | 256 | 34 | |||||||||||
Non-GAAP adjusted net income (loss) from continuing operations | $ | 760 | $ | (1,456 | ) | $ | 547 | $ | (6,914 | ) | ||||||
Net income (loss) per diluted share from continuing operations | (0.12 | ) | (0.42 | ) | (0.49 | ) | (0.90 | ) | ||||||||
Acquired intangible amortization | 0.03 | 0.08 | 0.09 | 0.26 | ||||||||||||
Unrealized loss (gain) on equity securities (1) | 0.05 | — | 0.06 | — | ||||||||||||
Unrealized loss (gain) on derivatives (2) | 0.01 | 0.02 | 0.09 | 0.08 | ||||||||||||
Litigation costs (3) | 0.08 | 0.02 | 0.20 | 0.04 | ||||||||||||
Gain on disposal of MD Office Solutions (4) | — | — | — | (0.17 | ) | |||||||||||
Tenant receivable (5) | — | — | — | 0.06 | ||||||||||||
Write off of software costs | — | — | — | 0.01 | ||||||||||||
Severance and retention costs (9) | 0.02 | — | 0.05 | — | ||||||||||||
Financing costs (6) | 0.01 | 0.01 | 0.03 | 0.05 | ||||||||||||
COVID-19 Protection Equipment (7) | — | — | — | 0.02 | ||||||||||||
SBA PPP Loan forgiveness (8) | — | — | — | (0.83 | ) | |||||||||||
Income tax (benefit) provision | (0.02 | ) | — | 0.02 | 0.01 | |||||||||||
Non-GAAP adjusted net income (loss) per basic share from continuing operations (10) | $ | 0.05 | $ | (0.29 | ) | $ | 0.04 | $ | (1.38 | ) | ||||||
Non-GAAP adjusted net income (loss) per diluted share from continuing operations (10) | $ | 0.05 | $ | (0.28 | ) | $ | 0.04 | $ | (1.36 | ) |
(1) Reflects adjustments for any unrealized gains or losses in equity securities.
(2) Reflects adjustments for any unrealized gains or losses in derivatives value.
(3) Reflects one time litigation costs.
(4) Reflects the gain from the sale of MDOS.
(5) Reflects one-time write off in uncollectible tenant receivable.
(6) Reflects financing costs from our credit facilities.
(7) Reflects purchases related to COVID -19 Protection Equipment.
(8) Reflects the forgiveness of the Paycheck Protection Program.
(9) Reflects the severance expense for our former Healthcare division CEO and other employees.
(10) Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and the sum of individual items may not equal the total.
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(In thousands)
For The Three Months Ended |
Healthcare | Construction | Investments | Star Equity Corporate | Total | ||||||||||||||
Net income (loss) from continuing operations (10) | $ | (598 | ) | $ | 975 | $ | (561 | ) | $ | (1,700 | ) | $ | (1,884 | ) | |||||
Depreciation and amortization | 330 | 489 | 58 | — | 877 | ||||||||||||||
Interest expense | 117 | 77 | (9 | ) | — | 185 | |||||||||||||
Income tax (benefit) provision | (367 | ) | — | — | — | (367 | ) | ||||||||||||
EBITDA from continuing operations | (518 | ) | 1,541 | (512 | ) | (1,700 | ) | (1,189 | ) | ||||||||||
Unrealized loss (gain) on equity securities (1) | — | — | 834 | — | 834 | ||||||||||||||
Unrealized loss (gain) on derivatives (2) | — | 153 | — | — | 153 | ||||||||||||||
Litigation costs (3) | 1,187 | — | — | — | 1,187 | ||||||||||||||
Stock-based compensation | 1 | 6 | — | 99 | 106 | ||||||||||||||
Severance and retention (9) | 272 | — | — | 3 | 275 | ||||||||||||||
Financing costs (6) | 17 | 98 | 17 | — | 132 | ||||||||||||||
Non-GAAP adjusted EBITDA from continuing operations | $ | 959 | $ | 1,798 | $ | 339 | $ | (1,598 | ) | $ | 1,498 |
For The Three Months Ended |
Healthcare | Construction | Investments | Star Equity Corporate | Total | ||||||||||||||
Net income (loss) from continuing operations (10) | $ | 853 | $ | (1,338 | ) | $ | (155 | ) | $ | (1,501 | ) | $ | (2,141 | ) | |||||
Depreciation and amortization | 321 | 489 | 50 | — | 860 | ||||||||||||||
Interest expense | 74 | 100 | 86 | — | 260 | ||||||||||||||
Income tax (benefit) provision | — | — | — | — | — | ||||||||||||||
EBITDA from continuing operations | 1,248 | (749 | ) | (19 | ) | (1,501 | ) | (1,021 | ) | ||||||||||
Unrealized loss (gain) on equity securities (1) | — | — | (30 | ) | 27 | (3 | ) | ||||||||||||
Unrealized loss (gain) on derivatives (2) | — | 95 | — | — | 95 | ||||||||||||||
Litigation costs (3) | — | — | — | 88 | 88 | ||||||||||||||
Stock-based compensation | 6 | 3 | — | 118 | 127 | ||||||||||||||
Financing costs (6) | 13 | 39 | — | — | 52 | ||||||||||||||
COVID-19 Protection Equipment (7) | 23 | — | — | — | 23 | ||||||||||||||
Non-GAAP adjusted EBITDA from continuing operations | $ | 1,290 | $ | (612 | ) | $ | (49 | ) | $ | (1,268 | ) | $ | (639 | ) |
For The Nine Months Ended |
Healthcare | Construction | Investments | Star Equity Corporate | Total | ||||||||||||||
Net income (loss) from continuing operations (10) | $ | (1,314 | ) | $ | 153 | $ | (794 | ) | $ | (5,206 | ) | $ | (7,161 | ) | |||||
Depreciation and amortization | 967 | 1,471 | 221 | — | 2,659 | ||||||||||||||
Interest expense | 264 | 269 | 131 | — | 664 | ||||||||||||||
Income tax (benefit) provision | 256 | — | — | — | 256 | ||||||||||||||
EBITDA from continuing operations | 173 | 1,893 | (442 | ) | (5,206 | ) | (3,582 | ) | |||||||||||
Unrealized loss (gain) on equity securities (1) | — | — | 834 | — | 834 | ||||||||||||||
Unrealized loss (gain) on derivatives (2) | — | 1,298 | — | — | 1,298 | ||||||||||||||
Litigation costs (3) | 2,955 | — | — | — | 2,955 | ||||||||||||||
Stock-based compensation | 5 | 17 | — | 300 | 322 | ||||||||||||||
Tenant receivable (5) | — | — | — | — | — | ||||||||||||||
Severance and retention (9) | 703 | — | — | 3 | 706 | ||||||||||||||
Write off of software costs | — | — | — | — | — | ||||||||||||||
Financing costs (6) | 45 | 259 | 65 | — | 369 | ||||||||||||||
COVID-19 Protection Equipment (7) | — | — | — | — | — | ||||||||||||||
SBA PPP Loan forgiveness (8) | — | — | — | — | — | ||||||||||||||
Non-GAAP adjusted EBITDA from continuing operations | $ | 3,881 | $ | 3,467 | $ | 457 | $ | (4,903 | ) | $ | 2,902 |
For The Nine Months Ended |
Healthcare | Construction | Investments | Star Equity Corporate | Total | |||||||||||||||
Net income (loss) from continuing operations (10) | $ | 5,313 | $ | (5,563 | ) | $ | (284 | ) | $ | (3,986 | ) | $ | (4,520 | ) | ||||||
Depreciation and amortization | 998 | 1,450 | 176 | — | 2,624 | |||||||||||||||
Interest expense | 189 | 456 | 87 | — | 732 | |||||||||||||||
Income tax (benefit) provision | 34 | — | — | — | 34 | |||||||||||||||
EBITDA from continuing operations | 6,534 | (3,657 | ) | (21 | ) | (3,986 | ) | (1,130 | ) | |||||||||||
Unrealized loss (gain) on equity securities (1) | — | — | (30 | ) | 13 | (17 | ) | |||||||||||||
Unrealized loss (gain) on derivatives (2) | — | 398 | — | — | 398 | |||||||||||||||
Litigation costs (3) | — | — | — | 213 | 213 | |||||||||||||||
Stock-based compensation | 120 | 3 | — | 266 | 389 | |||||||||||||||
Gain on disposal of MD Office Solutions (4) | (847 | ) | — | — | — | (847 | ) | |||||||||||||
Tenant receivable (5) | — | 323 | — | — | 323 | |||||||||||||||
Write off of software costs | — | 70 | — | — | 70 | |||||||||||||||
Financing costs (6) | 89 | 142 | — | — | 231 | |||||||||||||||
COVID-19 Protection Equipment (7) | 82 | — | — | 82 | ||||||||||||||||
SBA PPP Loan forgiveness (8) | (2,959 | ) | (1,220 | ) | — | — | (4,179 | ) | ||||||||||||
Non-GAAP adjusted EBITDA from continuing operations | $ | 3,019 | $ | (3,941 | ) | $ | (51 | ) | $ | (3,494 | ) | $ | (4,467 | ) |
(1) Reflects adjustments for any unrealized gains or losses on equity securities.
(2) Reflects adjustments for any unrealized gains or losses in derivatives value.
(3) Reflects one time litigation costs.
(4) Reflects the gain from the sale of MDOS.
(5) Reflects one-time write off in uncollectible tenant receivable.
(6) Reflects financing costs from our credit facilities.
(7) Reflects purchases related to COVID -19 personal protection equipment.
(8) Reflects the forgiveness of the Paycheck Protection Program.
(9) Reflects the severance and retention expense for our former Healthcare division CEO and other employees.
(10) Reflects the reclassification of prior year Diagnostic Services and Diagnostic Imaging net income into Healthcare segment and intercompany elimination from Construction and Investments segments.
Supplemental Debt Information
(Unaudited)
(In thousands)
A summary of the Company’s credit facilities are as follows:
Amount | Weighted-Average Interest Rate | Amount | Weighted-Average Interest Rate | |||||||||
Revolving Credit Facility - eCapital KBS | $ | 909 | 9.00 | % | $ | 3,131 | 6.00 | % | ||||
Revolving Credit Facility - eCapital EBGL | 2,595 | 9.00 | % | 1,652 | 6.00 | % | ||||||
Revolving Credit Facility - Webster | 7,484 | 5.64 | % | 7,016 | 2.60 | % | ||||||
Total Short-term Revolving Credit Facilities | $ | 10,988 | 6.71 | % | $ | 11,799 | 3.98 | % | ||||
eCapital - Star Loan Principal, net | $ | 864 | 9.25 | % | $ | 1,070 | 6.25 | % | ||||
Short Term Loan | $ | 864 | 9.25 | % | $ | 1,070 | 6.25 | % | ||||
Total Short-term debt | $ | 11,852 | 6.90 | % | $ | 12,869 | 4.17 | % |
Supplemental Segment Information
(Unaudited)
(In thousands)
Three Months Ended |
Nine Months Ended |
|||||||||||||||
2022 | 2021 (1) | 2022 | 2021 (1) | |||||||||||||
Revenue by segment: | ||||||||||||||||
Healthcare | $ | 13,137 | $ | 14,807 | $ | 40,467 | $ | 42,984 | ||||||||
Construction | 11,107 | 14,052 | 39,544 | 34,035 | ||||||||||||
Investments | 159 | 475 | 475 | 475 | ||||||||||||
Intersegment elimination | (159 | ) | (475 | ) | (475 | ) | (475 | ) | ||||||||
Consolidated revenue | $ | 24,244 | $ | 28,859 | $ | 80,011 | $ | 77,019 | ||||||||
Gross profit (loss) by segment: | ||||||||||||||||
Healthcare | $ | 2,725 | $ | 3,256 | $ | 9,579 | $ | 9,263 | ||||||||
Construction | 3,132 | 541 | 7,203 | (759 | ) | |||||||||||
Investments | 100 | 425 | 253 | 299 | ||||||||||||
Intersegment elimination | (158 | ) | (475 | ) | (474 | ) | (475 | ) | ||||||||
Consolidated gross profit | $ | 5,799 | $ | 3,747 | $ | 16,561 | $ | 8,328 | ||||||||
Income (loss) from continuing operations by segment: | ||||||||||||||||
Healthcare | $ | (1,036 | ) | $ | 955 | $ | (953 | ) | $ | 2,627 | ||||||
Construction | 1,149 | (956 | ) | 680 | (6,341 | ) | ||||||||||
Investments | 97 | 123 | 236 | 278 | ||||||||||||
Star equity corporate and intersegment elimination | (1,701 | ) | (2,006 | ) | (5,207 | ) | $ | (4,526 | ) | |||||||
Segment loss from operations | $ | (1,491 | ) | $ | (1,884 | ) | $ | (5,244 | ) | $ | (7,962 | ) | ||||
Depreciation and amortization by segment: | ||||||||||||||||
Healthcare | $ | 330 | $ | 321 | $ | 967 | $ | 998 | ||||||||
Construction | 489 | 489 | 1,471 | 1,450 | ||||||||||||
Investments | 58 | 50 | 221 | 176 | ||||||||||||
Total depreciation and amortization | $ | 877 | $ | 860 | $ | 2,659 | $ | 2,624 |
(1) Segment information has been recast for all periods presented to reflect Healthcare as one segment. Intercompany elimination previously allocated to Investments have been reclassified to a separate line.
Source: Star Equity Holdings, Inc.